Drug intelligence / Profile preview

sodium thiosulfate + methylene blue

Development stage: Unknown
Modality: Small Molecules
Administration: Intravenous

Overview

A combination of sodium thiosulfate and methylene blue that has been studied as an antidote for cyanide poisoning. Sodium thiosulfate functions as a sulfur donor that converts cyanide to less toxic thiocyanate through the rhodanese enzyme pathway, while methylene blue is a thiazine dye that can form methemoglobin which binds to cyanide. However, this combination is less effective than the standard treatment protocol of sodium nitrite with sodium thiosulfate for cyanide poisoning.

Targets

TST (Thiosulfate sulfurtransferase)COX7C (Cytochrome c oxidase subunit 7C, mitochondrial)

Beyond the preview

Go deeper on sodium thiosulfate + methylene blue.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on sodium thiosulfate + methylene blue.

Explore the full profile